Your session is about to expire
← Back to Search
Bortezomib for Multiple Myeloma
Study Summary
This trial is testing a new combination of drugs to treat myeloma, compared to the current standard of care.
- Multiple Myeloma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2008 Phase 2 trial • 20 Patients • NCT00006184Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any other published papers that explore Bortezomib's effects?
"587 clinical trials have completed investigating bortezomib since 1997, when City of Hope Comprehensive Cancer Center first studied the medication. As of now, there are 249 ongoing trials, many based in Hackensack, New jersey."
Are there any available positions for volunteers in this research project?
"This trial is no longer active. It was originally posted on 6/24/2010 and had its last update on 5/6/2022. However, there are 827 other clinical trials involving multiple myeloma that are currently recruiting patients and 249 Bortezomib trials with open enrollment.."
How many people have been recruited for this clinical trial?
"This study is no longer recruiting new patients. It was initially posted on 6/24/2010 and updated for the last time on 5/6/2022. There are 827 other trials currently looking for participants with multiple myeloma and 249 studies involving Bortezomib that are still open to enrolling patients."
What are some conditions that Bortezomib can help ameliorate?
"Bortezomib is not only useful in treating mantle cell lymphoma, but also stem cell transplant, amyloidosis, and multiple myeloma."
What are the deleterious effects of Bortezomib on patients?
"Bortezomib's safety is estimated to be a 2 because, while there is data supporting its safety, no studies have been done yet to test its efficacy."
Share this study with friends
Copy Link
Messenger